Vaccines-2013 - OMICS Group

Recommendations

Info

Entomack Borrathybay et al., J Vaccines Vaccin 2013, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0183 rd International Conference onVaccines & VaccinationJuly 29-31, 2013 Embassy Suites Las Vegas, NV, USAConstruction and characterization of an acapsular mutant of Pasteurella multocida strainP-1059 (A:3)Entomack Borrathybay, Yu-Feng Zhang, Wulumuhan Nazierbieke and Feng-Juan GongCollege of Biology and Environmental Sciences, Jishou University, ChinaTo further investigate the role of capsule involved in virulence of Pasteurella multocida P-1059 (A:3), a hexB deleted mutantwas constructed by homologous recombination. The DNA replacement was confirmed by PCR, Reverse transcription(RT)-PCR and DNA sequencing. Experiments were conducted to compare the differences of biological characteristics such ascapsular structure, capsular polysaccharide content, virulence and serum resistance between the hexB deleted mutant of ΔhexBand wild-type strain P-1059, as well as the complemented strain P-1059C. And the ability of the acapsular mutant ΔhexB toinduced protection against wild-type challenge in chickens. Electron microscopy examination of the ΔhexB showed the absenceof capsular material compared to the P-1059 and P-1059C. The ΔhexB was sensitive to the bactericidal action of chicken serum,whereas the P-1059 and P-1059C were both resistant. The ΔhexB was highly attenuated in chickens by intravenously injection,and intramuscular administration of ΔhexB to chickens stimulated significant protection against P-1059 and the homologousstrain X-73(A:1). These results demonstrated that the capsule is a major virulence factor of Pasteurella multocida serotype A:3strains.Keywords: Pasteurella multocida; homologous recombination; knockout; capsule; virulence; vaccine.etmkb@jsu.edu.cnJ Vaccines Vaccin 2013ISSN: 2157-7560, JVV an open access journalVaccines-2013July 29-31, 2013Volume 4 Issue 5Page 148
Fatemeh Ghaffarifar et al., J Vaccines Vaccin 2013, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0183 rd International Conference onVaccines & VaccinationJuly 29-31, 2013 Embassy Suites Las Vegas, NV, USAImmune response to toxoplasma gondii by SAG1 encoded DNA vaccineFatemeh Ghaffarifar, Fariba Khoshzaban, Zohreh Sharifi, Kavous Solhjou, Abdolhossein Dalimi, Ghazal Shahpari and Salimeh GhaffarifarShahed University, IranIn recent years, Toxoplasmosis is of major medical and veterinary importance. In recent years, significant progress has beenmade in the identification of vaccine candidates which can induce a protective response. Most of the works has focused onsurface antigens of tachyzoites specially SAG1. In this research, after extraction of genomic DNA and PCR of SAG1 gene, thePCR product was cloned into pTZ57R/T vector MCS and sequenced. Sequence analysis showed that SAG1 gene sequence fromthe high virulent strain presented in this study (known as RH) had 100% sequence identity with P-Br strain, P strain and C Strainand high homology of 98% with RH strain and ZS1 strain.Then, SAG1 was subcloned into pcDNA3 and after transfection into CHO cells; the expression of SAG1 was confirmed bySDS-PAGE and Western blotting. Immunization by pcSAG1 to toxoplasmosis was evaluated in BALB/c mice. Anti-T.gondiiIgG values (OD) increased markedly in the pcSAG1, which were significantly higher than those of control groups (P
Page 1 and 2:
111 th OMICS Group ConferenceJuly 2
Page 3 and 4:
Medical SciencesISSNAddiction Resea
Page 5 and 6:
Impact Factors (IF) and Index Coper
Page 7 and 8:
111 th OMICS Group Conference3 rd I
Page 9 and 10:
Journal of Clinical & Cellular Immu
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Clinical Microbiology-2013OMICS Gro
Page 17 and 18:
Immunology Summit-2013OMICS Group i
Page 19 and 20:
Probiotics-2013OMICS Group is organ
Page 21 and 22:
Virology-2013OMICS Group is organiz
Page 23 and 24:
Page 25 and 26:
Because of heightened awareness of
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Ara Hovanessian, J Vaccines Vaccin
Page 35 and 36:
Nikolai Petrovsky, J Vaccines Vacci
Page 37 and 38:
Page 39 and 40:
Robert E. Sievers et al., J Vaccine
Page 41 and 42:
Xiao-Qing Wei, J Vaccines Vaccin 20
Page 43 and 44:
Campbell Bunce, J Vaccines Vaccin 2
Page 45 and 46:
Hong Xin, J Vaccines Vaccin 2013, 4
Page 47 and 48:
Diane Longo et al., J Vaccines Vacc
Page 49 and 50:
Track 33: Novel Approaches in Desig
Page 51 and 52:
Takashi Kei Kishimoto, J Vaccines V
Page 53 and 54:
Benjamin Petsch, J Vaccines Vaccin
Page 55 and 56:
A. Bennett Jenson et al., J Vaccine
Page 57 and 58:
Milan Raska et al., J Vaccines Vacc
Page 59 and 60:
Muhammad Ali A. Shah et al., J Vacc
Page 61 and 62:
Track 44: Vaccines against Infectio
Page 63 and 64:
Haval Shirwan, J Vaccines Vaccin 20
Page 65 and 66:
Rainer Fischer, J Vaccines Vaccin 2
Page 67 and 68:
Alwyn Rapose, J Vaccines Vaccin 201
Page 69 and 70:
Saroj Basak, J Vaccines Vaccin 2013
Page 71 and 72:
Gisela Gonzalez, J Vaccines Vaccin
Page 73 and 74:
Young Research ForumSession ChairPe
Page 75 and 76:
Humberto Hernandez et al., J Vaccin
Page 77 and 78:
Nisha Nair et al., J Vaccines Vacci
Page 79 and 80:
Leow Yee et al., J Vaccines Vaccin
Page 81 and 82:
Kaissar Tabynov et al., J Vaccines
Page 83 and 84:
Teena Mohan et al., J Vaccines Vacc
Page 85 and 86:
Track 5 & 95: Manufacturing, Produc
Page 87 and 88:
Graham Clarke, J Vaccines Vaccin 20
Page 89 and 90:
Obradovic Zarema et al., J Vaccines
Page 91 and 92:
Abdur Razzaque Sarker et al., J Vac
Page 93 and 94:
Omer Qutaiba B. Al-lela et al., J V
Page 95 and 96:
Page 97 and 98: Regina Heidenreich et al., J Vaccin
Page 99 and 100: Leow Y et al., J Vaccines Vaccin 20
Page 101 and 102: Zafer Kurugol et al., J Vaccines Va
Page 103 and 104: Ates Kara et al., J Vaccines Vaccin
Page 105 and 106: Yurong Tan et al., J Vaccines Vacci
Page 107 and 108: Deryabin P.N. et al., J Vaccines Va
Page 109 and 110: Xiao-Yong Fan et al., J Vaccines Va
Page 111 and 112: Byung Chul Kim et al., J Vaccines V
Page 113 and 114: STS. Chitradevi et al., J Vaccines
Page 115 and 116: Yan Liang et al., J Vaccines Vaccin
Page 117 and 118: 111 th OMICS Group Conference3 rd I
Page 119 and 120: Afshineh Latifynia et al., J Vaccin
Page 121 and 122: Hemanta Koley et al., J Vaccines Va
Page 123 and 124: Aleksandar Masic et al., J Vaccines
Page 125 and 126: Hassen Mamo, J Vaccines Vaccin 2013
Page 127 and 128: Oladipo Aina et al., J Vaccines Vac
Page 129 and 130: Aiswariya Chidambaram, J Vaccines V
Page 131 and 132: Birhanu Hurisa et al., J Vaccines V
Page 133 and 134: Ghaffarifar F et al., J Vaccines Va
Page 135 and 136: Mathan Periasamy et al., J Vaccines
Page 137 and 138: Rania Abdel Hay, J Vaccines Vaccin
Page 139 and 140: Samuel Teshome, J Vaccines Vaccin 2
Page 141 and 142: 111 th OMICS Group Conference3 rd I
Page 143 and 144: Birhanu Hurisa et al., J Vaccines V
Page 145 and 146: Dhrubajyoti Nag, J Vaccines Vaccin
Page 147: Belachew Etana et al., J Vaccines V
Page 151 and 152: Moustafa A.F. Abbas et al., J Vacci
Page 153 and 154: Prerna Chaudhary, J Vaccines Vaccin
Page 155 and 156: Sandeepkumar R. Chauhan et al., J V
Page 157 and 158: Veronica Rainone et al., J Vaccines
Page 159 and 160: Page 159
Page 161 and 162: Previous111 th OMICS Group Conferen
Page 163 and 164: PreviousWorld Congress and Expo onB
show all

Vaccines-2013 - OMICS Group

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?